Jennafer Dotson

Learn More
Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain, commonly L858R or deletions within exon 19, increase EGFR-driven cell proliferation and survival and are correlated with impressive responses to the EGFR inhibitors erlotinib and gefitinib in nonsmall cell lung cancer patients. Approximately 60% of acquired resistance to(More)
  • Reference Kim, J Dotson, Rey C, Lindsey J
  • 2015
S4 Fig incorrectly appears as a duplicate of File S5. Please view the correct file, which has been renamed S4 Fig below. S4 Fig. Leaf senescence of JA mutants and ethylene mutant ein2–1. Comparison of leaves from wild type WS and Col to coi1–37, aos and ein2–1. Leaves were treated with 200 μM of meJA and 1 ppm ethylene as designated in Experimental(More)
To minimize the risk of failure in clinical trials, drug discovery teams must propose active and selective clinical candidates with good physicochemical properties. An additional challenge is that today drug discovery is often conducted by teams at different geographical locations. To improve the collaborative decision making on which compounds to(More)
  • 1